



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Inbakicept

Cat. No.:	HY-P99661
CAS No.:	2135939-52-3
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Inbakicept, also known as N-803 (Nogapendekin alfa inbakicept), contains the IL-15 cytokine antibody Nogapendekin alfa (HY-P99759). Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). Inbakicept also increases degranulation and IFN γ production in cells ^[1] .	
IC₅₀ & Target	IL-15R α	
In Vitro	Inbakicept (0.01-1 nM; 20 hr) enhances human NK cell cytotoxicity and increases cytotoxic effector molecule expression ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity Assay ^[1]	
	Cell Line:	Daudi, Raji, CD19 ⁺ FL cells
	Concentration:	0.01 nM, 0.1 nM, and 1 nM
	Incubation Time:	20 hours
	Result:	Increased the human NK cell cytotoxicity on Daudi, Raji, CD19 ⁺ FL cells.
In Vivo	Inbakicept (0.2 mg/kg; i.v.; twice weekly, for 2 weeks) enhances rituximab-directed protection from a lethal Daudi lymphoma challenge in mouse model ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	SCID mice with Daudi models ^[1]
	Dosage:	0.02 mg/kg, 0.05 mg/kg, 0.1 mg/kg, and 0.2 mg/kg
	Administration:	Intravenous injection; twice weekly, for 2 weeks
	Result:	Enhanced rituximab-directed control of Raji lymphoma challenge.

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA